Developer docs
API playgroundTry for free, no card

Search company profiles

Tcelltech

Full company profile

uuid02lwb44

Namestring
Tcelltech
Legal namestring
Tcelltech GmbH
Websiteurl
tcelltech.eu
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Tcelltech GmbH is a Mannheim, Germany-based clinical-stage biotechnology company spun out of the German Cancer Research Center (DKFZ) in 2022, developing next-generation cancer immunotherapies through two integrated technology platforms: selecTCR, an AI bioinformatics classifier that identifies tumor-reactive T cell receptors (TCRs) within days for immediate cell manufacturing use, with an extension (predicTCR) that detects T cell signatures for predicting and monitoring immunotherapy responses; and nanoSMAR, a minimally-sized, non-toxic, non-immunogenic episomal DNA vector platform offering unlimited genetic cargo capacity for cell therapy, gene therapy, and regenerative medicine applications.

The proprietary pipeline consists of three clinical-stage assets: IDH1 SCA-VAC, a peptide vaccine targeting the IDH1R132H clonal driver mutation that completed a Phase I trial in 32 patients (21 grade 3, 11 grade 4) meeting both primary endpoints; H3 SCA-VAC, a peptide vaccine targeting the H3K27M mutation for diffuse midline gliomas, currently in Phase I in combination with Atezolizumab; and TCT-001, a first-in-class T cell therapy for glioblastoma engineered with nanoSMAR, with Phase 1 testing scheduled to start in 2026 following preclinical publication in Nature Communications. The company is led by Prof Dr Michael Platten (CEO, 2024 German Cancer Award recipient alongside BioNTech's Ugur Sahin), Dr Ed Green, Dr Richard Harbottle, Dr Jochen Dieselhorst, and Dr Mathias Turwitt.

Commercial activity centers on direct outlicensing of the nanoSMAR vector platform to cell and gene therapy companies globally through a business development function led by Dr Fritz Rudert, alongside a subscription-based predicTCR web tool (predictcr.com) for academic and industry dataset interrogation. The pipeline products are expected to advance through traditional pharmaceutical clinical and commercialization pathways. No commercial revenue, funding rounds, or licensing deal values are disclosed.

Short descriptiontext

Tcelltech GmbH is a Mannheim-based, DKFZ-spin-out biotech developing AI-guided T cell receptor discovery (selecTCR) and a non-viral DNA vector delivery platform (nanoSMAR) to advance cancer vaccines and T cell therapies, primarily through technology outlicensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMannheim, Germany
HQ citystring
Mannheim
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, T cell therapy, DNA vector platform, TCR identification, cancer vaccines
Industry6 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Immunotherapy Biotechnology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Outlicensing of nanoSMAR vector platform to interested parties for applications in cell and gene therapy and stem cells. The company is actively seeking licensing partners for the technology.

tcelltech.eu
2Cancer Vaccine Products
TypeOne Time License
Description

Development and potential commercialization of cancer vaccines (IDH1 SCA-VAC and H3 SCA-VAC) targeting driver mutations in brain tumors through clinical development stages.

tcelltech.eu
3T Cell Therapy Products
TypeOne Time License
Description

Development of TCT-001, a first-in-class T cell therapy for glioblastoma, with Phase 1 testing expected to start in 2026 using nanoSMAR platform.

tcelltech.eu
4AI Bioinformatics Services
TypeSubscription Recurring
Description

Web-based tool at predictcr.com for interrogating existing datasets to identify therapeutic T cell receptors and predict/monitor immunotherapy responses.

tcelltech.eu
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1selecTCR
Description

AI bioinformatics platform to identify tumor reactive T cell receptors.

tcelltech.eu
+5 more records
Core offering1 text field

Tcelltech develops and licenses two proprietary technology platforms for next-generation cancer immunotherapy: selecTCR, an AI bioinformatics platform that identifies tumor-reactive T cell receptors within days for cell manufacturing, and nanoSMAR, a minimally-sized episomal DNA vector platform providing robust and persistent gene expression for cell and gene therapy applications. The company also develops its own pipeline of cancer vaccines (IDH1 SCA-VAC, H3 SCA-VAC) targeting brain tumor driver mutations and a first-in-class T cell therapy (TCT-001) for glioblastoma, with the nanoSMAR platform outlicensed to interested parties for cell therapy, gene therapy, and regenerative medicine applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I trial with 32 patients (21 grade 3, 11 grade 4) met both primary endpoints with very promising results
+2 more records
Product overview1 text field

Tcelltech offers two main technology platforms for next-generation cancer immunotherapies: selecTCR (predicTCR), an AI bioinformatics platform for identifying tumor-reactive T cell receptors, and nanoSMAR, a DNA vector platform for cell and gene therapy delivery. The company has developed a pipeline of cancer vaccine products including IDH1 SCA-VAC and H3 SCA-VAC targeting common clonal driver mutations in brain tumors, as well as TCT-001, a T cell therapy product engineered with the nanoSMAR platform.

Product and service5 records
1selecTCR (predicTCR)
CategoryPlatform / Bioinformatics Software
Description

AI bioinformatics platform that identifies tumor-reactive T cell receptors within days using an AI-guided classifier and is immediately available for cell manufacturing; also serves as predicTCR to detect T cell signatures for predicting and monitoring response to immunotherapies, validated across melanoma, colorectal, pancreatic, lung, and brain cancer.

2nanoSMAR DNA Vector Platform
CategoryPlatform / DNA Vector Technology
Description

Novel, minimally-sized, episomal DNA vector platform with unlimited genetic cargo capacity providing robust and persistent gene expression with minimal disruption to cell homeostasis; non-toxic and non-immunogenic; applicable to cell therapy, gene therapy, and regenerative medicine.

3IDH1 SCA-VAC Cancer Vaccine
CategoryTherapeutic Product / Cancer Vaccine
Description

Peptide cancer vaccine targeting the IDH1R132H clonal driver mutation in brain tumors; completed Phase I with 32 patients (21 grade 3, 11 grade 4) meeting both primary endpoints with promising results.

4H3 SCA-VAC Cancer Vaccine
CategoryTherapeutic Product / Cancer Vaccine
Description

Peptide cancer vaccine targeting the H3K27M clonal driver mutation in brain tumors; in Phase I development in combination with Atezolizumab after first-in-human dosing.

5TCT-001 T Cell Therapy
CategoryTherapeutic Product / Cell Therapy
Description

First-in-class T cell therapy for glioblastoma patients using T cells engineered with a proprietary T cell receptor targeting a glioblastoma antigen, manufactured with the nanoSMAR platform; Phase 1 testing expected to start in 2026.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Germany-based TCR-based immunotherapy company developing adoptive cell therapies and TCR bispecifics. Closely comparable to Tcelltech in therapeutic modality, German biotech origin, and TCR-engineering focus, with a more advanced clinical pipeline.

TypeDirect peer
Description

Clinical-stage gene-edited allogeneic cell therapy company with TCR-T and CAR-T programs. Comparable as a cell therapy platform developer using engineered TCRs, though Cellectis focuses on gene editing rather than episomal vectors.

TypeDirect peer
Description

Develops personalized TCR-T cell therapies for solid tumors using neoantigen-targeted receptors. Comparable to Tcelltech's selecTCR + TCR-T combination, with emphasis on individualized TCR discovery (acquired by AstraZeneca in 2023).

TypeBroad incumbent
Description

German mRNA and immuno-oncology leader with multiple oncology vaccine and cell therapy programs. Relevant as a German oncology incumbent and as a referenced comparator (German Cancer Award shared with CEO Platten), but operating at much greater scale and breadth than Tcelltech.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-T and TCR-T programs using non-viral (piggyBac) gene delivery approaches. Comparable to Tcelltech's nanoSMAR strategy of using non-viral episomal delivery to engineer T cells, though Poseida is more advanced clinically.

6Medigene
TypeDirect peer
Description

German biotech focused on TCR-T immunotherapies for solid tumors, with an IND-stage pipeline. Highly comparable to Tcelltech by geography (Germany), modality (TCR-T), and stage (early-clinical).

TypeOthers
Description

Cell and gene therapy technology and services provider with longstanding Tcelltech collaboration. Comparable as an enabling technology participant in the cell therapy manufacturing value chain rather than a direct therapeutic competitor.

TypeDirect peer
Description

Clinical-stage TCR-T cell therapy company with approved Tecelra for synovial sarcoma. Directly comparable to Tcelltech as a TCR-T platform developer targeting solid tumors, though at a more advanced clinical and commercial stage.

TypeEmerging player
Description

Early-stage TCR-T cell therapy company focused on solid tumors, with TCR discovery and TCR-T manufacturing capabilities. Comparable as a smaller, emerging TCR-T player competing for similar partnership and capital pools as Tcelltech.

TypeOthers
Description

Cell and gene therapy technology provider of electroporation-based delivery platforms. Listed as a Tcelltech collaborator and comparable as a DNA/transgene delivery infrastructure provider serving the cell therapy market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tcelltech

Cancer Immunotherapy Biotechnologytcelltech.eu

Tcelltech GmbH is a Mannheim-based, DKFZ-spin-out biotech developing AI-guided T cell receptor discovery (selecTCR) and a non-viral DNA vector delivery platform (nanoSMAR) to advance cancer vaccines and T cell therapies, primarily through technology outlicensing.

What Tcelltech does

Tcelltech GmbH is a Mannheim, Germany-based clinical-stage biotechnology company spun out of the German Cancer Research Center (DKFZ) in 2022, developing next-generation cancer immunotherapies through two integrated technology platforms: selecTCR, an AI bioinformatics classifier that identifies tumor-reactive T cell receptors (TCRs) within days for immediate cell manufacturing use, with an extension (predicTCR) that detects T cell signatures for predicting and monitoring immunotherapy responses; and nanoSMAR, a minimally-sized, non-toxic, non-immunogenic episomal DNA vector platform offering unlimited genetic cargo capacity for cell therapy, gene therapy, and regenerative medicine applications.

The proprietary pipeline consists of three clinical-stage assets: IDH1 SCA-VAC, a peptide vaccine targeting the IDH1R132H clonal driver mutation that completed a Phase I trial in 32 patients (21 grade 3, 11 grade 4) meeting both primary endpoints; H3 SCA-VAC, a peptide vaccine targeting the H3K27M mutation for diffuse midline gliomas, currently in Phase I in combination with Atezolizumab; and TCT-001, a first-in-class T cell therapy for glioblastoma engineered with nanoSMAR, with Phase 1 testing scheduled to start in 2026 following preclinical publication in Nature Communications. The company is led by Prof Dr Michael Platten (CEO, 2024 German Cancer Award recipient alongside BioNTech's Ugur Sahin), Dr Ed Green, Dr Richard Harbottle, Dr Jochen Dieselhorst, and Dr Mathias Turwitt.

Commercial activity centers on direct outlicensing of the nanoSMAR vector platform to cell and gene therapy companies globally through a business development function led by Dr Fritz Rudert, alongside a subscription-based predicTCR web tool (predictcr.com) for academic and industry dataset interrogation. The pipeline products are expected to advance through traditional pharmaceutical clinical and commercialization pathways. No commercial revenue, funding rounds, or licensing deal values are disclosed.

Tcelltech firmographics

Firmographics
Name
Tcelltech
Legal name
Tcelltech GmbH
Website
https://tcelltech.eu
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Tcelltech GmbH is a Mannheim-based, DKFZ-spin-out biotech developing AI-guided T cell receptor discovery (selecTCR) and a non-viral DNA vector delivery platform (nanoSMAR) to advance cancer vaccines and T cell therapies, primarily through technology outlicensing.
Ownership category
akta.pro rank

Tcelltech industry classification

Industry
Product category
Cancer Immunotherapy Biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAMAK
Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cancer immunotherapy
  • T cell therapy
  • DNA vector platform
  • TCR identification
  • Cancer vaccines

Where Tcelltech is headquartered

Location

Headquarters

HQ city
Mannheim
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Tcelltech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Technology Licensing: Outlicensing of nanoSMAR vector platform to interested parties for applications in cell and gene therapy and stem cells. The company is actively seeking licensing partners for the technology.
  2. Cancer Vaccine Products: Development and potential commercialization of cancer vaccines (IDH1 SCA-VAC and H3 SCA-VAC) targeting driver mutations in brain tumors through clinical development stages.
  3. T Cell Therapy Products: Development of TCT-001, a first-in-class T cell therapy for glioblastoma, with Phase 1 testing expected to start in 2026 using nanoSMAR platform.
  4. AI Bioinformatics Services: Web-based tool at predictcr.com for interrogating existing datasets to identify therapeutic T cell receptors and predict/monitor immunotherapy responses.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Tcelltech product offering

Product offering

Core offering

Tcelltech develops and licenses two proprietary technology platforms for next-generation cancer immunotherapy: selecTCR, an AI bioinformatics platform that identifies tumor-reactive T cell receptors within days for cell manufacturing, and nanoSMAR, a minimally-sized episomal DNA vector platform providing robust and persistent gene expression for cell and gene therapy applications. The company also develops its own pipeline of cancer vaccines (IDH1 SCA-VAC, H3 SCA-VAC) targeting brain tumor driver mutations and a first-in-class T cell therapy (TCT-001) for glioblastoma, with the nanoSMAR platform outlicensed to interested parties for cell therapy, gene therapy, and regenerative medicine applications.

Product overview

Tcelltech offers two main technology platforms for next-generation cancer immunotherapies: selecTCR (predicTCR), an AI bioinformatics platform for identifying tumor-reactive T cell receptors, and nanoSMAR, a DNA vector platform for cell and gene therapy delivery. The company has developed a pipeline of cancer vaccine products including IDH1 SCA-VAC and H3 SCA-VAC targeting common clonal driver mutations in brain tumors, as well as TCT-001, a T cell therapy product engineered with the nanoSMAR platform.

Differentiator

Problem solved

Functional benefit

Brands

  • selecTCR: AI bioinformatics platform to identify tumor reactive T cell receptors.
  • nanoSMAR
  • IDH1 SCA-VAC
  • H3 SCA-VAC
  • TCT-001
  • predicTCR

Products and services

  • selecTCR (predicTCR) AI bioinformatics platform that identifies tumor-reactive T cell receptors within days using an AI-guided classifier and is immediately available for cell manufacturing; also serves as predicTCR to detect T cell signatures for predicting and monitoring response to immunotherapies, validated across melanoma, colorectal, pancreatic, lung, and brain cancer.
  • nanoSMAR DNA Vector Platform Novel, minimally-sized, episomal DNA vector platform with unlimited genetic cargo capacity providing robust and persistent gene expression with minimal disruption to cell homeostasis; non-toxic and non-immunogenic; applicable to cell therapy, gene therapy, and regenerative medicine.
  • IDH1 SCA-VAC Cancer Vaccine Peptide cancer vaccine targeting the IDH1R132H clonal driver mutation in brain tumors; completed Phase I with 32 patients (21 grade 3, 11 grade 4) meeting both primary endpoints with promising results.
  • H3 SCA-VAC Cancer Vaccine Peptide cancer vaccine targeting the H3K27M clonal driver mutation in brain tumors; in Phase I development in combination with Atezolizumab after first-in-human dosing.
  • TCT-001 T Cell Therapy First-in-class T cell therapy for glioblastoma patients using T cells engineered with a proprietary T cell receptor targeting a glioblastoma antigen, manufactured with the nanoSMAR platform; Phase 1 testing expected to start in 2026.

Quantifiable outcome

  • Phase I trial with 32 patients (21 grade 3, 11 grade 4) met both primary endpoints with very promising results
  • +2 more outcomes

Companies that use Tcelltech

Customer profile

Segments3 records

Ideal customer profiles3 records

Tcelltech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Tcelltech partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Tcelltech competitors and assessment

Company assessment

Direct peers

  • Immatics: Germany-based TCR-based immunotherapy company developing adoptive cell therapies and TCR bispecifics. Closely comparable to Tcelltech in therapeutic modality, German biotech origin, and TCR-engineering focus, with a more advanced clinical pipeline.
  • Cellectis: Clinical-stage gene-edited allogeneic cell therapy company with TCR-T and CAR-T programs. Comparable as a cell therapy platform developer using engineered TCRs, though Cellectis focuses on gene editing rather than episomal vectors.
  • Neogene Therapeutics: Develops personalized TCR-T cell therapies for solid tumors using neoantigen-targeted receptors. Comparable to Tcelltech's selecTCR + TCR-T combination, with emphasis on individualized TCR discovery (acquired by AstraZeneca in 2023).
  • Poseida Therapeutics: Clinical-stage cell therapy company developing CAR-T and TCR-T programs using non-viral (piggyBac) gene delivery approaches. Comparable to Tcelltech's nanoSMAR strategy of using non-viral episomal delivery to engineer T cells, though Poseida is more advanced clinically.
  • Medigene: German biotech focused on TCR-T immunotherapies for solid tumors, with an IND-stage pipeline. Highly comparable to Tcelltech by geography (Germany), modality (TCR-T), and stage (early-clinical).
  • Adaptimmune Therapeutics: Clinical-stage TCR-T cell therapy company with approved Tecelra for synovial sarcoma. Directly comparable to Tcelltech as a TCR-T platform developer targeting solid tumors, though at a more advanced clinical and commercial stage.

Broad incumbents

  • BioNTech: German mRNA and immuno-oncology leader with multiple oncology vaccine and cell therapy programs. Relevant as a German oncology incumbent and as a referenced comparator (German Cancer Award shared with CEO Platten), but operating at much greater scale and breadth than Tcelltech.

Others

  • Miltenyi Biotec: Cell and gene therapy technology and services provider with longstanding Tcelltech collaboration. Comparable as an enabling technology participant in the cell therapy manufacturing value chain rather than a direct therapeutic competitor.
  • MaxCyte: Cell and gene therapy technology provider of electroporation-based delivery platforms. Listed as a Tcelltech collaborator and comparable as a DNA/transgene delivery infrastructure provider serving the cell therapy market.

Emerging players

  • TCRcure Therapeutics: Early-stage TCR-T cell therapy company focused on solid tumors, with TCR discovery and TCR-T manufacturing capabilities. Comparable as a smaller, emerging TCR-T player competing for similar partnership and capital pools as Tcelltech.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Tcelltech social profiles

Digital presence

Tcelltech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tcelltech leadership team

Management profile

Number of profiles

Profiles6 records

Tcelltech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tcelltech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tcelltech

What does Tcelltech do?

Tcelltech develops and licenses two proprietary technology platforms for next-generation cancer immunotherapy: selecTCR, an AI bioinformatics platform that identifies tumor-reactive T cell receptors within days for cell manufacturing, and nanoSMAR, a minimally-sized episomal DNA vector platform providing robust and persistent gene expression for cell and gene therapy applications. The company also develops its own pipeline of cancer vaccines (IDH1 SCA-VAC, H3 SCA-VAC) targeting brain tumor driver mutations and a first-in-class T cell therapy (TCT-001) for glioblastoma, with the nanoSMAR platform outlicensed to interested parties for cell therapy, gene therapy, and regenerative medicine applications.

Is Tcelltech a public or private company?

Tcelltech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tcelltech founded?

Tcelltech was founded in 2022. It employs 1 to 10 people.

Where is Tcelltech based?

Tcelltech is headquartered in Mannheim, Germany, in the Europe region.

How does Tcelltech make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are cancer Vaccine Products, T Cell Therapy Products and AI Bioinformatics Services.

Who are Tcelltech's main competitors?

Direct peers on record are Immatics, Cellectis, Neogene Therapeutics, Poseida Therapeutics, Medigene and Adaptimmune Therapeutics. BioNTech is listed as a broad incumbent. Others are Miltenyi Biotec and MaxCyte. TCRcure Therapeutics is listed as an emerging player.

Does Tcelltech have an API?

No public API is recorded for Tcelltech.

What industry is Tcelltech in?

Tcelltech's product category is Cancer Immunotherapy Biotechnology. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals